Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of JK06 alone and in combination in advanced solid tumors
2024-512421-92-00Phase 2Authorised
- Sponsor
- Salubris Biotherapeutics
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of JK06 in cancer, non-small cell lung cancer (NSCLC), breast cancer and 10 more (6 arms), sponsored by Salubris Biotherapeutics. Primary endpoints: Maximum tolerated dose / optimal biologic dose / dose-limiting toxicity, Safety and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
JK06
03
Conditions
cancernon-small cell lung cancer (NSCLC)breast cancerrenal cell carcinoma (RCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-512421-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512421-92-00.